Adenomyosis
ICD-10 N80.0 · ICD-11 GA11

Adenomyosis: What to Do When First-Line Medical Management Has Not Worked

Clinical Scenario

This protocol addresses patients with adenomyosis whose symptoms — heavy menstrual bleeding and pelvic pain (dysmenorrhea) — have not responded adequately to first-line medical therapy. When the treatment goals of the initial approach are not reached at 6 months, a second-line strategy is warranted.

First-Line Treatment — Goals Not Reached

First-line options for adenomyosis include NSAIDs, tranexamic acid, combined oral contraceptives, the levonorgestrel-releasing intrauterine system, dienogest, and norethindrone acetate.

When these measures fail to achieve a meaningful reduction in heavy menstrual bleeding and dysmenorrhea at 6 months, escalation to a second-line approach is indicated.

Second-Line Approach (Partial Summary)

The next step involves a gonadotropin-releasing hormone (GnRH) agonist. The complete protocol — covering agent selection, duration, and the role of add-back hormone therapy — is available via the link below.

Treatment Goals

The aim is significant improvement in heavy menstrual bleeding, dysmenorrhea, and pelvic pain, along with a measurable reduction in uterine volume at 16 weeks.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jogc.2023.04.008

  1. Gonadotropin-releasing hormone (GnRH) agonists can be considered as a second-line agent for management of pain and heavy menstrual bleeding from adenomyosis; add-back hormones should be initiated if GnRH agonists are used longer than 6 months (strong, low).
  2. A large multicentre prospective study of 465 patients with symptomatic adenomyosis treated with triptorelin every 28 days for 3 to 6 months showed a significant improvement in heavy bleeding, dysmenorrhea, and pelvic pain, with only 14% experiencing hot flushes.
  3. A retrospective cohort study of 52 patients with MRI-confirmed adenomyosis treated with GnRH agonist (leuprorelin or goserelin), low-dose COC, or dienogest found that only GnRH agonists led to a significant reduction in uterine volume at 16 weeks post-treatment.
View source ↗